Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Metronidazole Vaginal Gel, 0.75%, the generic version of MetroGel-Vaginal® Gel, 0.75%, of Bausch Health US, LLC.

According to IQVIATM sales data for the 12 month period ending November 2021, the MetroGelVaginal® Gel, 0.75% market achieved annual sales of approximately $60.4 million*.

Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 476.35 as compared to the previous close of Rs. 485.65. The total number of shares traded during the day was 58865 in over 2475 trades.

The stock hit an intraday high of Rs. 485.55 and intraday low of 474.45. The net turnover during the day was Rs. 28246958.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 FinalApproval USFDA MetronidazoleVaginalGel